iRadimed (IRMD) Expected to Announce Quarterly Earnings on Thursday

iRadimed (NASDAQ:IRMD) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $0.49 per share and revenue of $21.5970 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. On average, analysts expect iRadimed to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

iRadimed Stock Down 4.2%

NASDAQ IRMD opened at $93.85 on Thursday. The business’s fifty day simple moving average is $97.65 and its 200-day simple moving average is $82.09. The firm has a market cap of $1.19 billion, a PE ratio of 56.88 and a beta of 1.11. iRadimed has a 52 week low of $47.48 and a 52 week high of $104.93.

iRadimed Announces Dividend

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

Insider Buying and Selling

In other news, CFO John Glenn sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, January 26th. The shares were sold at an average price of $100.65, for a total value of $503,250.00. Following the completion of the sale, the chief executive officer directly owned 2,262,500 shares of the company’s stock, valued at $227,720,625. The trade was a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 55,000 shares of company stock valued at $5,287,900 in the last ninety days. 36.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On iRadimed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new position in iRadimed in the 3rd quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the period. Virtus Advisers LLC acquired a new position in shares of iRadimed in the third quarter valued at approximately $117,000. Aquatic Capital Management LLC increased its stake in iRadimed by 210,400.0% during the 3rd quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 2,104 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in iRadimed during the 3rd quarter worth approximately $164,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on IRMD. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Roth Mkm set a $90.00 price objective on iRadimed in a report on Friday, October 31st. Lake Street Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Zacks Research raised iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.